2,2-dimethyl-5-((4-(trifluoromethoxy)phenylamino)methylene)-1,3-dioxane-4,6-dione | 1071540-59-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2,2-dimethyl-5-((4-(trifluoromethoxy)phenylamino)methylene)-1,3-dioxane-4,6-dione
• 英文别名: 5-[(4-(trifluoromethoxy)phenylamino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione；2,2-dimethyl-5-[[4-(trifluoromethoxy)anilino]methylene]-1,3-dioxane-4,6-dione；2,2-dimethyl-5-[[4-(trifluoromethoxy)anilino]methylidene]-1,3-dioxane-4,6-dione
• CAS: 1071540-59-4
• 化学式: C₁₄H₁₂F₃NO₅
• 分子量: 331.248
• InChiKey: USPMKWONXSBQPC-UHFFFAOYSA-N

物化性质

• 沸点：
  447.0±45.0 °C(Predicted)
• 密度：
  1.472±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  2,2-dimethyl-5-((4-(trifluoromethoxy)phenylamino)methylene)-1,3-dioxane-4,6-dione 在 三氯氧磷 作用下， 以 二苯醚 为溶剂， 反应 5.08h， 生成 N,N-Diethyl-N'-(6-trifluoromethoxy-quinolin-4-yl)-propane-1,3-diamine
  参考文献：
  名称：

  Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities

  摘要：

  A simple two-step synthesis method was used to make 51 B-ring-substituted 4-hydroxyquinolines allowing analysis of the effect of ring substitutions on inhibition of growth of chloroquine sensitive and resistant strains of Plasmodium falciparum, the dominant cause of malaria morbidity. Substituted quinoline rings other than the 7-chloroquinoline ring found in chloroquine were found to have significant activity against the drug-resistant strain of P. falciparum W2. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.12.037
• 作为产物：
  描述：

  丙二酸环(亚)异丙酯 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 2,2-dimethyl-5-((4-(trifluoromethoxy)phenylamino)methylene)-1,3-dioxane-4,6-dione
  参考文献：
  名称：

  Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities

  摘要：

  A simple two-step synthesis method was used to make 51 B-ring-substituted 4-hydroxyquinolines allowing analysis of the effect of ring substitutions on inhibition of growth of chloroquine sensitive and resistant strains of Plasmodium falciparum, the dominant cause of malaria morbidity. Substituted quinoline rings other than the 7-chloroquinoline ring found in chloroquine were found to have significant activity against the drug-resistant strain of P. falciparum W2. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.12.037

文献信息

• Aurora Kinase Modulators and Method of Use
  申请人：Amgen Inc.

  公开号：US20140336182A1

  公开（公告）日：2014-11-13

  The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式I的化合物，其中A1-8、D'、L1、L2、R1、R6-8和n在此处定义，并且具有调节各种蛋白激酶受体酶并因此影响与这些激酶活动相关的各种疾病状态和病况的能力的合成中间体。例如，这些化合物能够调节枢纽激酶，从而影响细胞周期和细胞增殖过程，以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物，以及治疗与枢纽激酶活性相关的疾病状态的方法。
• [EN] PAPD5 INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PAPD5 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CHILDRENS MEDICAL CENTER

  公开号：WO2020219729A1

  公开（公告）日：2020-10-29

  The present application provides compounds that are PAPD5 inhibitors and are useful in treating a variety of conditions such as cancer, telomere diseases, and aging-related and other degenerative disorders.

  本申请提供了一些PAPD5抑制剂化合物，可用于治疗各种疾病，如癌症、端粒疾病以及与衰老和其他退行性疾病相关的情况。
• Synthesis and biological evaluation of new nucleosides derived from trifluoromethoxy-4-quinolones
  作者：Kristína Plevová、Katarína Briestenská、Françoise Colobert、Jela Mistríková、Viktor Milata、Frédéric R. Leroux

  DOI：10.1016/j.tetlet.2015.07.031

  日期：2015.9

  The synthesis of new nucleoside derivatives from 6- and 7-trifluoromethoxy-4-quinolones is described. The present synthesis is a combination of the Gould–Jacobs reaction for the preparation of 4-quinolones and a modified Vorbrüggen reaction for the construction of nucleoside derivatives. The target compounds were tested against murine gammaherpesvirus MHV-68 type.

  描述了由6-和7-三氟甲氧基-4-喹诺酮合成新的核苷衍生物。目前的合成方法是Gould-Jacobs反应（用于制备4-喹诺酮）和改良的Vorbrüggen反应（用于构建核苷衍生物）的组合。测试了针对鼠类γ疱疹病毒MHV-68型的目标化合物。
• Aurora kinase modulators and method of use
  申请人：Cee Victor

  公开号：US20090069297A1

  公开（公告）日：2009-03-12

  The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式I的化合物，其中A1-8，D'，L1，L2，R1，R6-8和n在此定义，并且合成中间体，它们能够调节各种蛋白激酶受体酶，并因此影响与这些激酶活动相关的各种疾病状态和情况。例如，这些化合物能够调节极化激酶，从而影响细胞周期和细胞增殖过程，以治疗癌症和与癌症相关的疾病。本发明还包括包括这些化合物的药物组合物以及治疗与极化激酶活性相关的疾病状态的方法。
• AURORA KINASE MODULATORS AND METHOD OF USE
  申请人：Deak Holly

  公开号：US20100280008A1

  公开（公告）日：2010-11-04

  The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式I的化合物，其中A1-8、D'、L1、L2、R1、R6-8和n在此定义，并且合成中间体能够调节各种蛋白激酶受体酶，从而影响与这些激酶活动相关的各种疾病状态和条件。例如，这些化合物能够调节极化分裂激酶，从而影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物以及治疗与极化分裂激酶活性相关的疾病状态的方法。